Table 2.
Multivariate survival analysis in patients treated with total chemotherapy cycle ≤7
| Factors of OS | Pvalue | HR | 95% CI |
| Pathological stage (ypIII-II vs. ypI-0) | 0.020* | 4.237 | 1.252–14.29 |
| COD (< 460 vs. ≥ 460 mg/m2) | 0.021* | 1.972 | 1.106–3.521 |
| CA19–9 (≥ 35 vs. < 35 U/ml) | 0.247 | 1.448 | 0.774–2.709 |
| TRG (5–3 vs. 2–1) | 0.316 | 1.842 | 0.558–6.077 |
| Factors of MFS | Pvalue | HR | 95% CI |
| Pathological stage (ypIII-II vs. ypI-0) | 0.048* | 2.747 | 1.068–7.812 |
| COD (< 460 vs. ≥ 460 mg/m2) | 0.028* | 1.763 | 1.062–2.933 |
| CA19–9 (≥ 35 vs. < 35 U/ml) | 0.161 | 1.503 | 0.850–2.656 |
| Anemia (yes vs. no) | 0.114 | 1.514 | 0.906–2.530 |
| TRG (5–3 vs. 2–1) | 0.427 | 1.530 | 0.536–4.369 |
| Factors of DFS | Pvalue | HR | 95% CI |
| Pathological stage (ypIII-II vs. ypI-0) | 0.039* | 2.801 | 1.053–7.462 |
| COD (< 460 vs. ≥ 460 mg/m2) | 0.041* | 1.637 | 1.110–2.688 |
| CA19–9 (≥ 35 vs. < 35 U/ml) | 0.264 | 1.381 | 0.783–2.438 |
| TRG (5–3 vs. 2–1) | 0.499 | 1.398 | 0.529–3.690 |
* P < 0.05. Abbreviations: OS Overall survival, MFS Metastasis-free survival, DFS Disease-free survival, HR Hazard ratio, CI Confidence interval, COD Cumulative oxaliplatin dose, CA19–9 Carbohydrate antigen 19–9, TRG Tumor regression grade